<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033356</url>
  </required_header>
  <id_info>
    <org_study_id>SM3-PJ-13</org_study_id>
    <secondary_id>2013-004462-33</secondary_id>
    <nct_id>NCT02033356</nct_id>
  </id_info>
  <brief_title>ED95 of Lidocaine 1.0% for Filling the Adductor Canal</brief_title>
  <official_title>An Estimate of the ED95 of Lidocaine 1.0% for Filling the Adductor Canal When Placing an Adductor Canal Block in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective dose finding study is to estimate the minimal effective volume
      (ED95) for lidocaine 1.0% for filling the adductor canal when placing an adductor canal
      block. We will apply the Continual Reassessment Method (CRM) for estimating the ED95 and use
      an MRI scan to evaluate the main objective and ensure spread to the distal part of the
      adductor canal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the ED 95 for the volume needed to fill the adductor canal distally.</measure>
    <time_frame>MRI performed 15 minutes post block</time_frame>
    <description>This will be evaluated as a binary outcome using MRI; where the adductor canal is considered to be filled if the lidocaine injectate can be identified inside the canal in the first slice distally to the insertion of the adductor longus muscle on femur.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of volume on proximal spread to the femoral triangle</measure>
    <time_frame>MRI performed 15 minutes post block</time_frame>
    <description>Evaluated as a binary outcome using MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps muscle strength</measure>
    <time_frame>1 hour post block</time_frame>
    <description>To investigate the effect of volume on quadriceps muscle strength, assessed as maximum voluntary isometric contraction (MVIC) and evaluated as a binary outcome (reduction by more or less than 25%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pin prick test</measure>
    <time_frame>1 hour post block</time_frame>
    <description>To investigate the effect of volume on sensory block assessed by pin-prick in the saphenous innervation area and in the popliteal fossa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature discrimination test</measure>
    <time_frame>1 hour post block</time_frame>
    <description>To investigate the effect of volume on sensory block assessed by cold sensation using alchohol swabs, in the saphenous innervation area and in the popliteal fossa.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ACB with 30 ml lidocaine 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB with 25 ml lidocaine 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB with 20 ml lidocaine 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB with 15 ml lidocaine 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB with 10 ml lidocaine 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB with 5 ml lidocaine 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adductor canal block with lidocaine 1%</intervention_name>
    <description>US-guided adductor canal block</description>
    <arm_group_label>ACB with 30 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 25 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 20 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 15 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 10 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 5 ml lidocaine 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>ACB with 30 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 25 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 20 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 15 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 10 ml lidocaine 1%</arm_group_label>
    <arm_group_label>ACB with 5 ml lidocaine 1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-30 years

          -  Men

          -  American Society of Anesthesiologists' class 1

          -  Body Mass Index 18-25

        Exclusion Criteria:

          -  Allergy to study medication

          -  Earlier trauma or surgery to the lower limb

          -  Diabetes Mellitus - Contraindications to MRI
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pia Jaeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesia, HOC, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aleris-Hamlet Hospitals Copenhagen</name>
      <address>
        <city>SÃ¸borg</city>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Pia Jaeger</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>adductor canal block</keyword>
  <keyword>volunteers</keyword>
  <keyword>US-guided peripheral nerve block</keyword>
  <keyword>lower limb</keyword>
  <keyword>MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

